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The inflammatory potential of 12 types of alginate-based microspheres was assessed in a human whole 
blood model. The inflammatory potential could be categorized from low to high based on the four main 
alginate  microsphere types; alginate microbeads, liquefied core poly-L-ornithine (PLO)-containing 
microcapsules, liquefied core poly-L-lysine (PLL)-containing microcapsules, and solid core PLL-
containing microcapsules. No complement or inflammatory cytokine activation was detected for the 
Ca/Ba alginate microbeads. Liquefied core PLO- and PLL-containing microcapsules induced 
significant fluid phase complement activation (TCC), but with low complement surface deposition 
(anti-C3c), and a low proinflammatory cytokine secretion, with exception of an elevated MCP-
1(CCL2) secretion. The solid core PLL-containing microcapsules generated lower TCC but a marked 
complement surface deposition and significant induction of the proinflammatory cytokines interleukin 
(IL-1)β, TNF, IL-6, the chemokines IL-8 (CXCL8), and MIP-1α (CCL3) and MCP-1(CCL2). 
Inhibition with compstatin (C3 inhibitor) completely abolished complement surface deposition, 
leukocyte adhesion and the proinflammatory cytokines. The C5 inhibitions partly lead to a reduction of 
the proinflammatory cytokines. The leukocyte adhesion was abolished by inhibitory antibodies against 
CD18 and partly reduced by CD11b, but not by CD11c. Anti-CD18 significantly reduced the (IL-1)β, 
TNF, IL-6 and MIP-1α and anti-CD11b significantly reduced the IL-6 and VEGF secretion. MCP-1 
was strongly activated by anti-CD18 and anti-CD11b. In conclusion the initial proinflammatory 
cytokine responses are driven by the microspheres potential to trigger complement C3 (C3b/iC3b) 
deposition, leukocyte activation and binding through complement receptor CR3 (CD11b/CD18).  

























In the field of cell-encapsulation therapy, the host inflammatory responses to the transplanted devices 
remain a major challenge. In order to design functionally performing microspheres for cell-
encapsulation therapies it is of crucial importance to understand the interplay between the biomaterial 
and the host defense system.  The surface of the microspheres represents the interface between the 
material and the biological factors and is critical for the initial inflammatory reactions. Potentially, the 
early inflammatory reactions serve as the starting points for a chronic inflammatory state [1] and could 
determine the success or failure of a cell-encapsulation device upon transplantation. A functional 
microsphere containing encapsulated cells would require an adequate exchange of oxygen, nutrition 
and waste products at the transplantation site which is hampered by cellular overgrowth. In general, 
host proteins are immediately covering the biomaterials upon transplantation, and through 
conformational changed and activated proteins [2-4] serve as the starting point for inflammatory 
reactions and cellular adhesion. A connection between the physico-chemical properties of alginate-
based microspheres and the host responses are recognized as important for the functional performance, 
nevertheless, the direct correlation and mechanisms leading to cellular adhesion are only partially 
understood  [5]. Alginate is the collective term of unbranched polysaccharides consisting of the two 
sugar residues 1-4 β-D-mannuronic acid (M) and α-L-guluronic acid (G) in variable amounts of 
alternating or block structures with impact on its properties [6]. It is the most used material for cell 
encapsulation due to the ability to form gels under cell-friendly conditions [6], and  in combination 
with a low ability to bind proteins, alginate microbeads has been regarded as suitable candidates for 
cell encapsulation even in the clinical setting [5]. However, the combinations of alginate with 
polycations and different gelling protocols lead to variability in the final physico-chemical properties 
with consequences for in vivo performance.  
 
The complement system is easily activated upon contact with biomaterial surfaces [7]. C3 is the key 
protein of the complement cascade, and is abundantly present in plasma. In addition, C3 is found in the 
peritoneal fluid [8] as well as in subcutaneous and omental adipose tissue [9].  C3 is a contributor to the 
biomaterial-induced inflammation during blood contact [10], and recently C3 was demonstrated to be 

















meshes [11].  The complement system consists of a cascade of serine proteases acting in sequence, 
initiated through three different pathways: the classical pathway, the lectin pathway, and the alternative 
pathway. The first two can be activated through antibody binding or by pattern recognition, whereas 
the alternative pathway can be activated through spontaneous activation of C3 to nearby surfaces. All 
three pathways converge upon the activation of C3, which mainly serves as an amplification loop. The 
subsequent events lead to the formation of the C3 and C5 convertases and the formation of activation 
products. One  of the  activation products C5a is a strong chemoattractant and a potent contributor to 
inflammation [12]. The C3 convertase’s can be established on surfaces of biomaterials further 
accelerating the formation of C3 to C3b.  C3b is rapidly converted to iC3b, which is the main ligand 
for the leukocyte adhesion and phagocytosis receptor CR3 (CD11b/CD18) and a ligand also for CR4 
(CD11c/CD18).   
 
The interplay between complement and the leukocytes can be studied using a whole blood model based 
on specific blockage of thrombin for anticoagulation [13]. This is an efficient physiologically relevant 
model to study the earliest inflammatory events and gives the possibility to evaluate a set of 
microspheres under identical conditions. Using the whole blood model, we previously demonstrated 
differences between alginate-based microcapsules, prepared in the presence of a polycation, and 
alginate microbeads, prepared by gelling alginate droplets with divalent cations, in the ability to 
activate complement [14] and inflammatory cytokines [15].  
 
In the present study, the whole blood model was employed on microspheres to evaluate the 
inflammatory properties of 12 different alginate-based microspheres, divided into the following groups: 
alginate microbeads, liquefied core alginatepoly-L-ornithine (PLO) microcapsules, liquefied core 
alginatepoly-L-lysine (PLL) microcapsules and solid core alginatePLL microcapsules. Evident 
differences in the complement activation patterns were determined for various microspheres, which 
significantly contributes to correlation between the potential of inflammatory cytokines and the 


















2. Materials and Methods 
2.1 Reagents and materials 
The present study utilized ultrapure high G sodium alginate (Laminaria hyperborea, 67% G residues, 
UP-LVG) and intermediate G sodium alginate (Macrocystis pyrifera, 42% G residues, UP-100M) from 
FMC BioPolymer AS (Novamatrix, Norway) with further characteristics given in Table 1.  
Table 1.  
Chemical composition and sequence distribution obtained from 
1
H-NMR spectra of alginates used in 
this work. 
 




























0.67 0.55 0.12 0.21 0.05 0.09 0.5 12 187 1.99 1051 <100 <0.3 











a) FG, molar fraction of guluronic acid, FGG and FGGG are dyad and triad frequencies respectively  
b) NG>1 the average of number of consecutive units in the G blocks 
c) The weight average molecular weight  given in Dalton measured by SEC-MALLS  
d) The intrinsic viscosity was measured at 20oC in 0.1M NaCl aqueous solution in a Micro Ubbelohde viscometer. 
e) Content given by the manufacturer. 
 
Other reagents for microspheres formations were: D-mannitol BDH Anala R., VWR International (Ltd, 
Pool, England), analytical grade calcium chloride, barium chloride and Na-Citrate tribasic dehydrate 
were all from Merck, Darmstadt, Germany. Poly-L-lysine hydrochloride (P2658, lot nr.091K5120, 
MW 20900 Da), Poly-L-ornithine hydrobromide (P3530, lot nr. 48F503, MW 23000 Da) and HEPES 
(H4034), Zymosan A (Z-4250), LPS from E.coli strain 0111:B4 (Invivogen, San Diego, CA), PBS with 
calcium and magnesium, EDTA, paraformaldehyde, and BSA were all purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Non-pyrogenic sterile saline (0.9% NaCl) and endotoxin free, non-pyrogenic, 

















Reagents for the whole blood assay and analysis were as follows: The anti-coagulant lepirudin was 
obtained from Celgene Europe, Boudry, Switzerland. The C3 inhibitor compstatin analog 1MEW and 
CP20 [16] with a corresponding control peptide described in [15] was synthesized and kindly provided 
from the laboratory of Prof. John D. Lambris. A monoclonal anti-C5 antibody eculizumab (Soliris®, 
Alexion Pharmaceuticals, Lausanne, Switzerland) was used to inhibit C5. For inhibition of the CR3 
and CR4 receptors, the following antibodies were used; CD11b, ultra-leaf purified anti-mouse/human 
CD11b (Rat IgG2b clone M1/70 ) with the control ultra-leaf purified Rat IgG2b ; CD18, ultra-leaf 
purified anti-human CD18 (Mouse IgG1 clone TS1/18); CD11c, ultra-leaf purified anti-human CD11c 
(Mouse IgG1 clone 3.9) with the control ultra-leaf Mouse IgG1 clone MOPC-21 (all from Biolegend, 
San Diego, CA).  Other antibodies were anti-CD11b PE (BD Biosciences, San Jose, Ca), anti-CD14 
FITC (BD Biosciences, San Jose, CA), anti-human C5b-9 clone aE11 (Diatech, Oslo, Norway), 
biotinylated 9C4 (an in-house antibody described in [17]), FITC conjugated rabbit anti-human C3c 
(F0201), detection C3 and all its fragments except for C3a and C3d, and FITC conjugated poly- rabbit 
anti mouse (F0261) from Dako (Glostrup, Denmark). Streptavidin-PE was from BioLegend (San 
Diego, CA) and substrate reagent A and B from R&D Systems (Minneapolis, MN). Equipment for 
blood sampling included polypropylene vials (NUNC, Roskilde, Denmark) and BD vacutainer top 
(Belliver Industrial Estate, Plymouth, UK). 
 
2.2 Microsphere preparation 
The microspheres were made using filter-sterilized solutions under strictly sterile conditions, 
autoclaved equipment and sterile hood in all steps. Endotoxin was measured by Endpoint Chromogenic 
LAL assays  (Lonza) according to producers manual. The endotoxin content for the polycation 
solutions and gelling solutions were below 20 pg/ml. In brief, the alginate microbeads were made of a 




 ions in the molar ratio 50/1 in three different 
sizes,  the liquefied core alginatePLO and alginatePLL microcapsules were made of intermediate G 
alginate complexed with either PLO or PLL in two different concentrations and subsequently citrate-
treated and the solid core alginatePLL microcapsules were made of either intermediate G or high G 

















More detailed, the core alginates were made as previously described [18] using 1.8% UP-LVG or 1.8% 
UP-100M alginate (Novamatrix) dissolved in 300 mM M mannitol. The gelling solutions used for 
Ca/Ba microbeads were  1 mM BaCl2/50 mM CaCl2/150 mM mannitol/10 mM HEPES, whereas for 
the microcapsules 50 mM CaCl2/150 mM mannitol/10 mM HEPES gelling solution was used. For each 
microsphere type, 5 ml of alginate was dripped into the gelling bath using a high-voltage electrostatic 
bead generator operating at 7kV. The microcapsules were made using 4 needles of internal diameter 
(ID) size of 0.35 or 0.40 mm and flow of 10 ml/h per needle. The microbeads were made with single 
needle either of ID 0.25mm and with flow rate of alginate solution of 6ml/h, or of needle ID (mm) 
equal to 0.35mm or 0.4mm with the flow rate of alginate solution of 8ml/h. In all cases the microbeads 
were gelled for 10 min after the last droplet formation. Microcapsules were prepared by soaking the 
microbeads in polycation solutions (25 ml saline containing from 0.05 to 0.14 % PLL or 0.14% PLO) 
for 10 minutes, and further incubated in 0.1% UP-100M in saline for 10 min. Liquefied core 
microcapsules were made by an additional step incubating microcapsules in 10 ml Na-citrate solution 
(55 mM) for 10 minutes. Between each step the microspheres were washed in 30 ml saline. After the 
final step, microcapsules were dispersed in 12 ml of saline and 10 aliquots containing approximately 
0.5 ml of microspheres. The endotoxin content of the microspheres storing solutions was all below 20 
pg/ml. The microspheres diameters (N=30 for each type) were measured using a Nikon TMS 
microscope at resolution 10x and with an ocular (CFWE10xA/18 Nikon, Japan) containing an internal 
scale bar.  Before each whole blood assay, 0.5 ml microspheres were additionally divided into 10 
samples each containing approximately 50 µl of microspheres. The overview of microspheres 





















































UP100M 42 PLL 0.10 0.40 Ca
2+
 + 683 ±70 
APA Liquefied 
core 
UP100M 42 PLL 0.14 0.40 Ca
2+
 + 645 ±57 
APA Liquefied 
core 
UP100M 42  PLO 0.14 0.40 Ca
2+
 + 652 ±48 
         
APA Solid core UP100M 42 PLL 0.05 0.40 Ca
2+
 - 647 ±85 
APA Solid core UP100M 42 PLL 0.10 0.40 Ca
2+
 - 588 ±53 
 

















APA Solid core UP-LVG 67 PLL 0.10 0.40 Ca
2+
 - 572 ±22 
APA Solid core UP-LVG 67 PLL 0.05 0.35 Ca
2+
 - 573 ±40 
APA Solid core UP-LVG 67 PLL 0.10 0.35 Ca
2+
 - 554 ±26 
         
Ca/Ba 
microbeads  




 - 589 ±15 
Ca/Ba 
microbeads  




 - 477 ±32 
Ca/Ba 
microbeads  




 - 343 ±14 
 
Alginate characteristics are given in Table 1. The gelling solution designated as Ca
2+
:  50 mM CaCl2/150 mM 






1 mM BaCl2/50 mM CaCl2/150 mM 
mannitol/10 mM HEPES. PLL: Poly-L-lysine hydrochloride (P2658, MW 20900 Da), PLO: Poly-L-ornithine 
hydrobromide (P3530, MW 23000 Da). The polycation-containing microcapsules were made using four needles of 
different internal diameters, each with a flow of alginate solution of 10 ml/h. The Ca/Ba microbeads were made with a 
single needle of internal diameter 0.25 mm at the flow rate of alginate solution of 6 ml/h (needle) or at the flow rate of 
alginate solution of 8 ml/h using the needles of internal diameter 0.35 and 0.4 mm. The high voltage electrostatic 
bead generator was employed for all microsphere preparation operating at 7 kV.  
 
2.3 Whole blood model  
Whole blood from voluntary donors (N=3-7 donors per experiment as stated in the figures) was 
collected in polypropylene vials containing lepirudin (50 μg/ml). Polypropylen vials (NUNC 1.8 ml) 
were utilized for various microcapsules and controls following the previously established protocol [13, 
14], which includes a washing step in sterile saline (medical quality) followed by an aliquot step. 
Briefly, samples of 100 µl saline containing microspheres (approximately 50 µl), zymosan (10 µg) or 




) was added 
followed by the addition of 500 µl of blood. Samples were incubated for 60 and 240 minutes prior to 
complement inhibition by EDTA of final concentration equal to 10 mM. Aliquots of EDTA inactivated 
plasma were stored at -20
o
C prior to analysis. In the inhibitory experiments utilizing C3 inhibitor 
compstatin, the C5 inhibitor eculizumab, the ultra-leaf anti-CD11b, anti-CD18 or anti-CD11c or its 
controls, blood was pre-incubated with the inhibitors or PBS control prior to the addition to the stimuli 

















incubated blood was added to the microspheres samples. The final concentration of compstatin was10-
25 µM, eculizumab was 100 µg/ml and the ultra-leaf antibodies were 40 µg/ml.  
 
2.4 Complement  
Activation of complement in the fluid-phase was measured by the terminal soluble C5b-9 complement 
complex (TCC) by an ELISA using TCC specific capture Ab (aE11 reacting with a C9 neoepitope 
exposed only when C9 is incorporated in the C5b-9 complex) and detection Ab (biotinylated anti-
human C6) as described previously [19]. C5a was measured using Human C5a OptEIA Kit II (BD 
Biosciences). Optical density was measured using the Bio-Rad plate reader (Bio-Rad Laboratories, CA, 
USA) and analyzed further using Microplate Manager software (version 6.1).  
 
2.5 Cytokines 
Cytokines, including interleukins, chemokines and growth factors,  were analyzed by a multiplex 
cytokine assay (Bio-Plex Human cytokine 15-Plex Panel using a Bio-Plex 200 system and Bio-Plex 
Pro Wash station; all from Bio-Rad Laboratories, Hercules, CA) containing the following analytics: IL-
1 beta (IL-1β), IL-1 receptor antagonist (IL-1RA), IL-6, IL-8 (CXCL8), IL-10, interferon gamma (INF-
γ), chemokine (C-X-C motif) ligand 10 (IP-10 or CXCL10), monocyte chemoattractant protein-1 
(MCP-1, or CCL2), macrophage inflammatory protein-1-alfa (MIP-1α, or CCL3), platelet derived 
growth factor-BB (PDGF-BB), regulated upon activation T-cell expressed and secreted (RANTES, or 
CCL5), tumor necrosis factor alfa (TNF), vascular endothelial growth factor (VEGF), hepatocyte 
growth factor (HGF), and macrophage migration inhibitory factor (MIF). The multiplex analyzes were 
performed as recommended by the producer using half amounts of beads. In addition, IL-8 and TNF 


















2.6 Leukocyte CD11b expression 
Expression of monocyte and granulocyte CD11b was determined after 60 minutes incubation in whole 
blood. Blood (50 µl) was fixed in 0.05% PFA, and further stained by PE anti-CD11b (BD Biosciences) 
and FITC anti-CD14 (BD Biosciences) for 15 minutes. Thereafter, the samples were transferred to 500 
µl EasyLyse erythrocyte lysis buffer following the 15 minutes incubation. Monocytes and granulocytes 
were analyzed in Epics XL-MCL Flow cytometer (Beckman Coulter, Inc., Brea, CA, USA), gated in a 
SSC/CD14 plot and the CD11b activation was measured as the median fluorescence intensity (MFI).  
 
2.7 C3c deposition 
Selected alginate microspheres were incubated in human plasma (300 µl) or in whole blood (500 µl) 
for various times. In addition, microspheres incubated either in plasma, serum or whole blood for four 
hours was evaluated. Then the surface was stained for C3c using FITC-conjugated rabbit anti-human 
C3c (50 µg/ml) FITC conjugated poly-rabbit anti-mouse (50 µg/ml) used as a control. The surface of 
the microspheres was evaluated using CLSM (Zeiss LSM 510 Meta, Carl Zeiss MicriImaging GmbH, 
Gôttingen, Germany) at the CMIC core facility at NTNU with the following settings: excitation 
wavelength 488 nm, emission wavelength BP 505-530. Optical cross-sections through the equator were 
taken using 488 nm laser and differential interference contrast (DIC), and 3D projections were made 
from z-stacks through the entire microspheres using the 488 nm laser only. The employed objective for 
imaging was C-Apochromat 10x/0.45W.  
 
2.8 Statistical methods  
The comparison of various microspheres with saline control was done by a one-way analysis of 
variance (ANOVA) with Dunnets post-test for comparison with the saline control, and with Tukey`s 
post-test for comparison between the various groups of microspheres (PLL liquefied, PLO liquefied, 
PLL solid, Beads) or individual microspheres. The data was log-transformed since N was too small to 

















rank test (N≥7) was used for comparison of various inhibitors with their respective controls. Both tests 
were performed using Graph Pad Prism 5 for Windows version 5.03. Data were considered statistically 
significant with P<0.05.  
2.9 Ethics 
The use of human whole blood for basal experiments was approved by the Regional Ethic Committee 
at NTNU in Norway. The experiments were performed in accordance with their guidelines.  
 
3 Results 
3.1 Fluid-phase complement activation (TCC)  
TCC was variably induced and was dependent on the microsphere compositions (Fig. 1). The liquefied 
core PLL microcapsules induced a prominent and significant activation of TCC as compared to the 
other microspheres categories (PLO liquefied, PLO solid or Beads) after four hours incubation (Fig. 1).  
 
Figure 1. Fluid phase C5b-9 (TCC) after incubation of microspheres in human whole blood for four 

















LPS are the positive controls. Bars are means ± SEM, N = 5 (N=4 for microbeads made with needle 
ID 0.25 and 0.4 mm). * compared to the saline control, # comparison between microspheres 
categories. #P ≤ 0.05, ##P ≤ 0.01, ###P ≤ 0.001, ####P ≤ 0.0001 (*correspondingly). 
The liquefied core PLL microcapsules also induced a prominent and significant activation as compared 
to the other microspheres already after one hour incubation (Suppl. S1). The liquefied core PLO 
microcapsules induced a lower amount of TCC, but statistically significant more than the saline control 
and the Ca/Ba Beads (Fig. 1 and Suppl. Fig. S1). The corresponding PLL microcapsules with a solid 
core induced significant amount of TCC but still substantially lower amount than the liquefied core 
counterparts (Fig. 1). The amount of TCC induced by the Ca/Ba microbeads was significant lower than 
the saline control (Fig. 1). The other variables induced smaller and mostly non-significant differences 
(Supplementary Table 1) that can be summarized in the following; For the solid core PLL 
microcapsules the highest concentration of PLL (0.1%) induced more TCC than the lower 
concentration ( 0.05%), while the opposite tendency was found for the liquefied core microcapsules 
(Fig. 1). The intermediate G solid core PLL microcapsules showed a slight elevation compared to 
microcapsules made of high G alginate (Fig. 1). The solid core PLL microcapsules containing high G 
alginate were made with either needle sizes of 0.35 or 0.4 mm. This resulted in no differences in the 
mean diameters, but with a slightly elevated TCC response by the microcapsules made by the 0.35 mm 
needles between otherwise comparable conditions. The alginate microbeads made with needles of 0.25, 
0.35 or 0.4 mm resulted in  mean diameters of 343, 477, 589 µm respectively,  but did not show any 
difference in the TC  response.  
 
3.2 Complement C3c deposition on the surface of microspheres 
The deposition of C3c on the surface of microspheres was detected after incubating in human lepirudin 
anticoagulated plasma.  A massive deposition of C3c with accumulation between the incubation times 
of six and 24 hours was found on the solid core microcapsules (Fig. 2). The citrate treatment resulted in 
a lower deposition with only minor deposition after six hours and with some accumulation after 24 
hours on the liquefied core microcapsules. A lower deposition was observed on the PLO compared to 

















significant C3c deposition was detected on microcapsules made of both high G and intermediate G. 
The C3c deposition was not detected on Ca/Ba beads, which is consistent with previously published 
data [15], and therefore  these data are not shown. Additionally we compared the C3c deposition 
between whole blood, lepirudin anti-coagulated plasma and serum (same donor), which in all cases 
showed to be deposited, but with some variability in the patterns of deposition  (Supplementary S2). 
 
Figure 2. C3c deposition on the surface of selected microcapsules after incubation in lepirudin 
plasma (human) for 6 and 24 hours. The microcapsule composition of the selected types: APA using 
intermediate G alginate and 0.14 % PLL with liquefied core, APA using intermediate G alginate and 
0.14 % PLO with liquefied core, APA using intermediate G alginate and 0.1% PLL with solid core, 


















3.3  Cytokines 
The secretion profiles of selected proinflammatory cytokines, including chemokines and growth 
factors, are shown in Fig. 3 and Suppl. Fig. S3. The most potent inducers of the inflammatory 
cytokines were the solid core PLL microcapsules (all six microcapsule types prepared using different 
conditions as described in Table 2), showing statistically significant increase of TNF, IL-6, IL-8, MIP-
1α and VEGF as compared to the saline control. The liquefied core microcapsules generally induced 
lower amounts of the cytokines, with significant lower amounts of TNF, IL-1β, IL-8 and MIP-1α as 
compared to the solid microcapsules.  One exception to the low cytokine induction, was a strong and 
significant elevation of MCP-1 by the PLL containing liquefied core microcapsules, and a small but 
significant elevation of IL-8 as compared to the saline control. No clear differences in the cytokine 
response patterns could be detected between the solid core PLL microcapsules prepared using either 
high G or intermediate G alginate. The Ca/Ba Beads did not induce statistically significant amount of 
cytokines compared to the saline control, and induced statistically lower amounts of all the 
inflammatory cytokines as compared to the solid microcapsules, and lower MCP-1 and IL-8 as 
compared to the liquefied PLL microcapsules. The different size of the Ca/Ba Beads did neither have 





















Figure 3. Inflammatory mediators (TNF, IL-1β, IL-6, MCP-1(CCL2), IL-8 (CXCL8) and MIP-1α 
(CCL3)) secreted after four hours incubation of microspheres in human whole blood. T0: baseline 
value at blood withdrawal, SAL: background activation from saline, ZYM and LPS are the positive 
controls. Bars are means ± SEM, N = 5 or N=4 for the microbeads prepared using needle ID 0.25 mm 
and 0.4 mm, respectively. * compared to the saline control, # compared to microspheres categories. 
#P ≤ 0.05, ##P ≤ 0.01, ###P ≤ 0.001, ####P ≤ 0.0001 (*correspondingly). 
 
3.4 CD11b expression 
The monocyte and granulocyte CD11b expression was determined after one hour incubation of 
microspheres in whole blood (Fig. 4). The Ca/Ba microbeads did not induce CD11b expression above 
the saline control, and were inducing statistically lower CD11b expression compared to the other 
microspheres with exception of the monocytes population given PLO liquefied microcapsules. The 
polycation containing microcapsules all induced increased CD11b expression reaching statistical 
significance in five out of nine microcapsule types compared to the saline.  The liquefied core PLL-
containing microcapsules revealed statistical significance, while non-significant elevated values were 
determined for PLO-containing liquefied core microcapsules. The solid core PLL-containing 
microcapsules made of high G alginate exhibited statistically significant enhanced CD11b expression 
in case of the highest concentration of PLL (0.1%). In contrast, the opposite trend was observed for 


















Figure 4. Monocyte and granulocyte CD11b expression after one hour exposure of various 
microspheres to human whole blood. T0: baseline value at blood withdrawal, SAL: background 
activation from saline, ZYM and LPS are the positive controls. Bars are means ± SEM, N = 3. *  
compared to the saline control, 
#
 compared to microspheres categories. 
#
P ≤ 0.05, 
##





P ≤ 0.0001and  
*
P ≤ 0.05. 
 
3.5 Complement inhibition  
The observed differences in complement fluid and solid phase activation and cytokine responses 
between the solid and liquefied core PLL-containing microcapsules made us to proceed with 
complement inhibition to further elucidate the underlying mechanisms behind the inflammatory 
response caused by these microspheres. The experiments for liquefied and solid core PLL-containing 
microcapsules with inhibition of C3 are shown in Fig. 5. The inhibition of C3 resulted in statistically 
significant reduction of TCC and C5a thus confirming that the liquefied core microcapsules activated a 
strong complement response. The data also demonstrated that the activation mechanism was through 
the C3 activation with subsequent formation of C5a and TCC, and not caused by a direct cleavage of 
C5 which could have been the alternative. IL-8 showed an opposite activation profile than TCC with 

















secretion statistically significant only for the solid core microcapsules while the liquefied core 
microcapsules resulted in less pronounced response. 
 
 
Figure 5. The impact of C3 inhibition on TCC, C5a and IL-8(CXCL8) after incubation with liquefied 
core or solid core PLL microcapsules in human whole blood for four hours. Bars are means ± SEM, 
N=6 for TCC and IL-8, and N=4 for C5a. * P<0.05 compared to corresponding native condition, # 
P<0.05 compared to corresponding control (Ctr) peptide. 
 
The solid core PLL (0.1%) microcapsule made of high G alginate was studied in whole blood by 
inhibition of complement either at the level of C3 or C5 (Fig. 6). A strong C3c deposition was found on 
the solid core microcapsules under native conditions, with added control peptide or C5 inhibitor (Fig. 
6). Under these conditions, the cell adhesion to the surface of microcapsules was also observed. In 
contrast, the inhibition of C3 resulted in complete absence of the C3c deposition as well as the cell 
adhesion. This pointed to a strong connection between the complement surface activation and the cell 
adhesion. The inflammatory cytokines IL-1β, TNF, IL-6 and IL-8 were statistically significantly 


















Figure 6. Effect of C3 and C5 inhibition on C3c deposition, cell adhesion and inflammatory cytokines 
after four hours incubation with solid core PLL microcapsules in whole blood. Bars graphs are 
means ± SEM, N=5. * P<0.05 compared to the native condition, # P<0.05 to the control (Ctr) peptide. 
Scale bars are 100 μm. 
 
3.6 CD11b, CD18 or CD11c blockage 
The integrin CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are receptors for iC3b, which is the 

















microcapsule surface was abolished (Fig. 7).  A reduced cell-adhesion was observed by blocking 
CD11b while no apparent reduction could be observed when blocking CD11c. We proceeded also with 
measuring the cytokine response after CD18, CD11b and CD11c blockage (Fig. 7). CD18 blockage 
reduced the secreted amounts of TNF, IL-1β, IL-6 and MIP-1α and increased the secretion of MCP-1 
significantly. The CD11b blockages lead to significant reduction of IL-6 and VEGF, and a strong 
induction of MCP-1. The CD11c blockages induced a slight significant reduction of IL-6 and partly 
TNF, although less pronounced (Suppl. S4). No effect on the MCP-1 induction was detected by the 
CD11c blockage (Suppl. S4). Despite a reduction of IL-8 with the C3 and C5 inhibition, no effect 
could be found on IL-8 by the antibody blockage (Suppl. S5). However, upon a combined blockage of 
CD11b or CD18 with C5 inhibition, the IL-8 secretion was significantly reduced. The controls (native 
or IgG isotype control) were also reduced by the C5 inhibition, but a small but significant additional 
reduction was observed with the CD11b as compared to the controls (Suppl. S5). MCP-1 was also 
significant and substantially reduced by the C5 inhibition, although the chemokine was not fully taken 
down by the combined inhibition of CD11b or CD18 with C5 (Suppl. S5). A slight additional effect of 
C5 inhibition on the IL-6 secretion after CD18 blockage was also found, whereas this effect was not 


















Figure 7. Effect of inhibitory antibodies against CD18, CD11b and CD11c on the leukocyte  adhesion 
on solid core PLL microcapsules and the inflammatory cytokine secretion after four hours 
incubation in human whole blood. Bars are means ± SEM, N=7. * P<0.05 blockage compared with 





















The present study revealed that the inflammatory potential of alginate-based microspheres assessed in a 
human whole blood model varied due to the microsphere preparation conditions, and can be 
categorized as inert for the Ca/Ba microbeads, low for the liquefied core PLO-containing 
microcapsules, intermediate for the liquefied core PLL-containing microcapsules and high for the solid 
core PLL-containing microcapsules. Differences in the PLL concentration, type of alginate (high G 
versus intermediate G) or needle size tested for solid core PLL-containing microcapsules showed 
minor effect on the inflammatory potential. The inflammatory properties of the Ca/Ba microbeads were 
not influenced by the size ranging from 343 to 589 µm. The change of alginate type from previously 
used high viscosity (UP-MVG) [14, 15] to the low viscosity alginate (UP-LVG) did not change the 
inflammatory properties of the Ca/Ba microbeads.  In conclusions, three major variabilities seemed to 
be of importance for the inflammatory potential in the present study; 1) alginate Ca/Ba microbeads vs. 
polycation-containing microcapsules; 2) liquefied vs. solid core of microcapsules; 3) PLO vs. PLL 
used as a polycation for preparation of microcapsules. In summary, the microspheres surface reactivity 
to complement is suggested as the major reason for the observed differences among microspheres 
tested in this study. The surface activation of complement subsequently leads to the cell adhesion 
mainly through CD11b/CD18 with consequence for the cytokine release.  The underlying relationship 
between the preparation conditions of microspheres and biological mechanisms are discussed in the 
next sections.  
The alginate-based polycation-containing microcapsules in the present study influenced the 
complement activation patterns either by inducing substantial complement activation at the solid phase 
(microcapsule surface) or in the fluid phase.  The liquefied core microcapsules activated complement 
in the fluid phase (TCC) but with low activation at the solid phase (surface deposition of C3b/iC3b). 
The opposite pattern was presented by the solid core microcapsules with a massive surface deposition 
of C3b/iC3b. Our data highlights the difference of complement potency when activated at the solid 
phase as compared to the fluid phase, and emphasizes the importance of examining both phases when 
using complement activation as readout for biocompatibility. The reason for the distinct difference 

















physico-chemical properties of microcapsules discussed in the next sections.  
The complement C3 convertase is commonly  initiated through the covalent binding of C3b or C4b to 
hydroxyl groups but can also be initiated by covalent binding to amino groups [20]. Since we 
previously did not find any activation of the classical or lectin pathway by poly-L-lysine 
microcapsules, but elevated levels of the activation product Bb from the alternative pathway [14], we 
suggest that the C3 convertase activity is due to a direct binding through C3 tick-over activation to the 
poly amine groups of the alginate microcapsules. The analysis of the membrane of alginatePLL 
microcapsules has  shown that PLL is exposed in the outermost surface of microcapsules [18, 21] 
either as a complex with alginate or as a random coil exposing free amino groups [21].  Our data 
demonstrate a trend of increased complement reactivity with increased concentration of PLL for the 
solid core PLL-containing microcapsules using high G alginate, which probably reflected an increased 
amount of free amino groups to react with C3. Accordingly, the lower C3c deposition on the liquefied 
core microcapsules could be the result of a more complete complexation between the PLL and the 
alginate due to increased availability of the alginate chains when presented in a soluble (non-gelled) 
form.  
The fast and strong TCC generated by the liquefied core microcapsules can be proposed to be related to 
the microcapsule stability. Liquefied core microcapsules are less stable than solid microcapsules [22]. 
We observed small fragments stained with C3c from the surface of the liquefied core microcapsules 
containing PLL possibly resulting from decomposed microcapsule membranes, and indicating a low 
stability. In comparison, the PLO coated microcapsules gave significantly less TCC. The use of PLO 
instead of PLL is shown to increase the stability of alginatepolycation microcapsules [23-25]. PLO 
differs from PLL by containing three methyl groups instead of four in the pendant moiety, which is 
responsible for more stable complexes with a negatively charged biopolymer as DNA  [26].  The lower 
complement activation by the liquefied core PLO-containing microcapsules may be a consequence of 
stronger complexation with the negatively charged alginate resulting in improved stability and lower 
exposure of free amino groups compared to PLL-containing microcapsules. The TCC formation was 
only slightly elevated by the microcapsules containing intermediate G instead of high G alginate. 
Although these differences should be interpreted with great caution, they could be related to the  

















microcapsules made of intermediate G alginate [23]. In addition, the ability to bind more PLL but less 
alginate in the outer coating by intermediate G alginate [22] can further explain our data.  Overall, the 
complement reactivity patterns for various alginate-based microcapsules may be explained by the 
existing knowledge on their physico-chemical and functional properties. We show here that the 
complement activation per se could be a supplementary method to study the surface properties of the 
microspheres.  
The complement deposition on the microsphere surfaces was measured as C3c deposition, which is the 
larger part of C3. C3c is present both in its native (C3) and activated states (C3b and iC3b), thus it is 
not possible to distinguish between a non-activated and activated C3c deposition. However, upon the 
formation of the C3 convertases (C4b2a and C3bBb) or the C5 convertases (C4b2a3b or C3bBbC3b) 
on the microspheres surfaces, more C3 will be converted to C3b/iC3b, which will be manifested as 
accumulated C3c. Massive deposition, as in the case of the solid core PLL microcapsules (Fig. 2), thus 
indicate C3 activation products. The deposited C3b is further cleaved to iC3b [7], which serves as the 
main ligand for the complement receptor CR3 present on the plasma membrane of monocyte and 
granulocyte. The accumulated iC3b could therefore serve as the starting point for cell adhesion. The C3 
deposition on the solid core PLL-containing microcapsule surface was completely abolished by 
blocking C3 using compstatin.  Importantly, this also resulted in the lack of adhering cells that 
demonstrates the link between the surface complement reactivity and the cell adhesion. Further, the 
secretion of the inflammatory cytokines was blocked by the C3 inhibition, which is consistent with our 
previous data showing that a broad panel of inflammatory mediators were dependent on complement 
activation [15]. Whether the cytokine induction was due to fluid- or surface-deposited complement 
activating products was, however, not previously elucidated. By blocking the β2 integrin chain, CD18, 
which forms complex with CD11b (CR3 receptor) or CD11c (CR4 receptor), the cell adhesion was 
fully inhibited. Further on, a partly inhibition of the cell-adhesion was found by CD11b blockage, 
while no apparent inhibition was observed with the CD11c blockage. This confirms that the CR3 
receptor is responsible for the leukocyte adhesion to the solid PLL microcapsule surface. Moreover, the 
blockage of either CD18 or CD11b led to a selective reduction of TNF, IL-1β, MIP-1α, IL-6, and 
VEGF, and an induction of the MCP-1.  While our data indicated also that CD18 was the most 
important receptor for induction of these cytokines, CD11b selectively contributed to IL-6 and VEGF 

















indicate that MCP-1 is induced by another mechanism not dependent on the cell-adhesion.  We have 
previously shown that the MCP-1 was completely blocked by C3 inhibition [15], and here we also 
show that the C5 inhibition is reducing MCP-1,  thus still pointing to a solely complement dependent 
effect.  Together with the consistence between TCC, C5a and MCP-1 profiles seen from the 
microspheres screening, a possible explanation could be that MCP-1 is induced by activated iC3b 
fragments of the fluid phase released from the microspheres membranes of liquefied microcapsules 
with subsequent binding to the CR3 receptor. The present study exemplifies that complement 
activation at the surface induces a different cytokine pattern from the fluid state activation, and further 
emphasizes that the surface adhesion is highly important in understanding the interplay between 
implanted biomaterials and biological factors.  
The strong TCC response induced by the liquefied core microcapsules corresponded with elevated C5a 
levels. Since both these activating products can be blocked by C3 inhibition, we confirmed that the 
activation was due to an initial activation by C3 and not a direct activation of C5, which could be an 
alternative mechanism [27]. The difference between the liquefied and solid core microcapsules to 
induce cytokines, and their opposite effects to trigger TCC and C5a show that the cytokine secretion 
was not caused by TCC or C5a under the current conditions. Complement products as C5a and toll-like 
receptors (TLRs) have been shown to act in synergy [28, 29]. Thus, the inflammatory reactions caused 
by the alginate microspheres could potentially be a result of cross-talking between these systems. 
Soluble alginate rich in mannuronic acid (>86%) is able to induce TNF in monocytes through 
mechanisms involving CD14 [30] TLR2 and TLR4 [31]. Recently it was demonstrated that purified 
alginate rich in guluronic acid as used currently, did not activate TLRs [32]. Soluble PLL is able to 
stimulate TNF in human monocytes through CD14 [33],  but crosslinked with alginate as in PLL 
microcapsules the CD14 is not involved [15]. Our present and previous data show that blockage of C3 
completely abolishes the inflammatory cytokine responses by the alginate microspheres, pointing to a 
solely complement mediated mechanism.   
The role of C5a is multiple, and shown to be a potent chemoattractant with pleiotropic roles in 
inflammation [34], to induce IL-8 by endothelial cells [35] and NF-kB activation in peripheral blood 
leukocytes [36]. Further on, C5a is a potent activator of CR3 (CD11b/CD18) on blood granulocytes 

















increase in leukocyte CD11b (CR3) expression.  Increased CD11b expression could secondly impact 
the ability of leukocytes to adhere to the complement-activated surface. The effect action of C5a on the 
inflammatory cytokines by the alginate microspheres could therefore be an indirect effect through cell-
adhesion as a consequence of CD11b activation increasing the binding of CR3 to C3b/iC3b at the 
microspheres surface. On the other hand, there might be a possibility for C5a to act in synergy with the 
integrin receptors in the cytokine induction for at least some of the cytokines, such as IL-8. One finding 
that may point in this direction was the combined blockage of C5 and CD11b leading to a significant 
reduction of the IL-8. The reduced IL-8 response by direct inhibition of complement C3 or C5 show 
that IL-8 is connected to the complement activation, and the combination of CD11b with C5 inhibitor 
resulted in an slight reduction of IL-8. A direct blockage did however not give any reduction of IL-8 in 
the present experiments. These discrepancies could be related to the high sensitivity of IL-8 to 
complement activation.   
 
One should be careful to directly transfer our data from whole blood to an in vivo situation upon 
transplantation. Nevertheless, some interesting similarities and discrepancies between the findings in 
the whole blood and after implantation of empty microspheres should be mentioned. In mice studies 
using various strains, a stronger host cell adhesion has been observed to polycation containing 
microcapsules as compared to alginate microbeads [5, 38-40]. Further, the PLO-containing 
microcapsules exhibited lower cell adhesion than PLL-containing microcapsules after short-time (7 
days) transplantation into the peritoneal cavity of C57BL6 mice [39]. In addition, identical types of 
microspheres either transplanted intraperitoneally in Wistar rats or evaluated in human whole blood 
showed consistency between host cell adhesion in vivo and the inflammatory response in vitro 
(Vaithilingam et al., unpublished). Alginate microbeads tested under in vivo conditions also exhibit the 
cell adhesion dependent on the choice of animal model [5] or mice strains [38-40]. The lack of ability 
to predict the cell adhesion for Ca/Ba microbeads indicates that other mechanisms could in addition be 
involved in inducing the cell adhesion. By inhibiting complement C3 or C5aR, the amount of immune 
cell infiltrated into the implanted meshes was half of that observed for wild-type littermates [11] 
pointing to complement as an important contributor to the observed immune response. Since the 

















leukocytes, this model is an efficient tool to elucidate the inflammatory potential of the alginate-based 
microspheres as well as to understand the mechanisms behind the complex host reactions involved 
upon implantation of biomaterials.  
 
Conclusion 
The whole blood model is efficient for the study of the initial inflammatory responses to different types 
of alginate microspheres. The solid PLL microcapsules were the most inflammatory due to the massive 
binding of C3 to the surface with subsequent cell-adhesion and induction of inflammatory cytokines.  
The liquefied microcapsules caused an intermediate inflammatory response. The inflammatory 
potential of the liquefied PLO microcapsules was lower than the liquefied PLL microcapsule. The 
alginate microbeads were the prototype of an inert material, not inducing inflammatory readouts above 
the saline background. Our studies revealed a surprising distinguish between the complement reactivity 
at the microcapsules surface and the fluid-phase activation which had considerable impact on the 
cytokine activating potential.  The complement C3 activation at the surface with subsequent cell-
adhesion through the binding of CR3 (CD11b/CD18) receptor, seems to be the crucial mechanism for 
the cytokine release. The exception from this is the monocyte chemoattractant protein-1, MCP-1, 
which seems to be induced by complement activating products of the fluid phase and the CR3 receptor.  
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